Pramipexole augmentation in treatment-resistant major depressive disorder

Curcumin as an Add-On to Antidepressive Treatment

(2013) Joseph Bergman et al.   CLINICAL NEUROPHARMACOLOGY

Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study

(2013) Jose A. Franco-Chaves et al.   JOURNAL OF AFFECTIVE DISORDERS

A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder

(2013) Cristina Cusin et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in Women With Major Depressive Disorder

(2012) In Kyoon Lyoo et al.   AMERICAN JOURNAL OF PSYCHIATRY

Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder

(2012) Danial Khajavi et al.   JOURNAL OF CLINICAL PSYCHIATRY

Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder

(2010) Chi-Un Pae et al.   CNS DRUGS

Pramipexole for stage 2 treatment-resistant major depression: An open study

(2010) Takeshi Inoue et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Diagnostic guidelines for bipolar depression: a probabilistic approach

(2009) Philip B Mitchell et al.   BIPOLAR DISORDERS

The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials

(2009) Chi-Un Pae et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY